Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Ovarian cancer is the leading cause of death from gynecologic tumors in the western world.
Most patients have relapses, and responses to subsequent therapies are generally short-lived.
Currently, the population that can benefit from PARPi is mainly focusing on BRCAm, then
homologous-recombination deficiency patients. Limited data revealed the ORR was only 3-4% in
homologous recombination proficiency patients with PARPi therapy. New treatments are urgently
needed to improve patient outcomes.
To explore the efficacy and safety of Fuzuloparib in combination with Arsenic trioxide
therapy in platinum-resistance relapsed Ovarian cancer patients.